Eli Lilly and Co Expected to Earn FY2018 Earnings of $4.91 Per Share (LLY)

Eli Lilly and Co (NYSE:LLY) – Analysts at SunTrust Banks raised their FY2018 earnings per share (EPS) estimates for shares of Eli Lilly and in a note issued to investors on Thursday. SunTrust Banks analyst J. Boris now expects that the company will post earnings of $4.91 per share for the year, up from their prior estimate of $4.82. SunTrust Banks also issued estimates for Eli Lilly and’s FY2019 earnings at $5.41 EPS, FY2020 earnings at $6.16 EPS and FY2022 earnings at $7.39 EPS.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping the consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $0.95 earnings per share.

Several other research analysts have also recently issued reports on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group restated a “hold” rating and issued a $80.00 target price on shares of Eli Lilly and in a report on Friday, February 2nd. Leerink Swann raised their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $92.02.

Eli Lilly and (LLY) opened at $76.23 on Monday. The company has a market cap of $83,936.48, a P/E ratio of 17.81, a price-to-earnings-growth ratio of 1.39 and a beta of 0.23. Eli Lilly and has a one year low of $73.69 and a one year high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is -1,039.95%.

In related news, insider Donald A. Zakrowski sold 900 shares of Eli Lilly and stock in a transaction on Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the sale, the insider now owns 4,130 shares in the company, valued at $334,901.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 259,610 shares of company stock worth $22,727,406. 0.20% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Airain ltd bought a new stake in shares of Eli Lilly and during the 2nd quarter valued at $567,000. Buckingham Asset Management LLC boosted its holdings in shares of Eli Lilly and by 21.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after buying an additional 568 shares in the last quarter. BSW Wealth Partners boosted its holdings in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after buying an additional 27 shares in the last quarter. Mirador Capital Partners LP boosted its holdings in shares of Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after buying an additional 619 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Eli Lilly and by 166.7% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock valued at $36,818,000 after buying an additional 269,038 shares in the last quarter. Hedge funds and other institutional investors own 76.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Co Expected to Earn FY2018 Earnings of $4.91 Per Share (LLY)” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/12/eli-lilly-and-co-expected-to-earn-fy2018-earnings-of-4-91-per-share-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply